{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:44:55Z","timestamp":1790318695171,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.gene.2025.149966","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T16:34:20Z","timestamp":1765989260000},"page":"149966","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Navigating the winding road toward precision prostate cancer care"],"prefix":"10.1016","volume":"984","author":[{"given":"Syed","family":"Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adith S.","family":"Arun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac Yi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William K.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.gene.2025.149966_b0005","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.gene.2025.149966_b0010","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.3390\/cancers15092552","article-title":"Management of advanced prostate cancer in the precision oncology era","volume":"15","author":"Gillette","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.gene.2025.149966_b0015","first-page":"293","article-title":"Studies on prostatic cancer - I the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.gene.2025.149966_b0020","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.gene.2025.149966_b0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","article-title":"Clinical and biological features of neuroendocrine prostate cancer","volume":"23","author":"Yamada","year":"2021","journal-title":"Curr. Oncol. Rep."},{"issue":"12","key":"10.1016\/j.gene.2025.149966_bib351","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.gene.2025.149966_b0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/OP.21.00206","article-title":"Recent advances in the management of metastatic prostate cancer","volume":"18","author":"Sayegh","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.gene.2025.149966_b0035","article-title":"Metastatic hormone-sensitive prostate cancer: toward an era of adaptive and personalized treatment","volume":"43","author":"Hamid","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"4","key":"10.1016\/j.gene.2025.149966_b0040","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.euf.2024.07.013","article-title":"Systemic treatments for metastatic prostate cancer in 2024","volume":"10","author":"Gizzi","year":"2024","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.gene.2025.149966_b0045","doi-asserted-by":"crossref","DOI":"10.1177\/11795549241277181","article-title":"The rapidly evolving treatment landscape of metastatic hormone-sensitive prostate cancer","volume":"18","author":"Yu","year":"2024","journal-title":"Clin. Med. Insights Oncol."},{"key":"10.1016\/j.gene.2025.149966_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1530580","article-title":"Treatment of metastatic castration-resistant prostate cancer: review of current evidence and synthesis of expert opinions on radioligand therapy","volume":"15","author":"Poon","year":"2025","journal-title":"Front. Oncol."},{"issue":"10336","key":"10.1016\/j.gene.2025.149966_b0055","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.gene.2025.149966_b0060","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.gene.2025.149966_b0065","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"28","key":"10.1016\/j.gene.2025.149966_b0075","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1200\/JCO.21.02517","article-title":"Orteronel for metastatic hormone-sensitive prostate cancer: a multicenter, randomized, open-label phase III trial (SWOG-1216)","volume":"40","author":"Agarwal","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.gene.2025.149966_b0080","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.gene.2025.149966_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2025.07.042","article-title":"Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers","volume":"188","author":"Grist","year":"2025","journal-title":"Cell"},{"issue":"17_suppl","key":"10.1016\/j.gene.2025.149966_b0090","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5006","article-title":"Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes","volume":"43","author":"Attard","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gene.2025.149966_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.2999","article-title":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study","author":"Fizazi","year":"2025","journal-title":"Ann. Oncol."},{"issue":"24","key":"10.1016\/j.gene.2025.149966_b0105","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.gene.2025.149966_b0110","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"5_suppl","key":"10.1016\/j.gene.2025.149966_b0115","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.2025.43.5_suppl.155","article-title":"Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety","volume":"43","author":"Bryce","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"5_suppl","key":"10.1016\/j.gene.2025.149966_b0120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.LBA18","article-title":"Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial","volume":"43","author":"Agarwal","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"5_suppl","key":"10.1016\/j.gene.2025.149966_b0125","volume":"43","author":"Fizazi","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.gene.2025.149966_b0130","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.gene.2025.149966_b0135","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","article-title":"Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study","volume":"84","author":"Abida","year":"2023","journal-title":"Eur. Urol."},{"issue":"18","key":"10.1016\/j.gene.2025.149966_b0220","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.gene.2025.149966_b0140","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.gene.2025.149966_b0145","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/pros.23484","article-title":"Intraductal\/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer","volume":"78","author":"Isaacsson Velho","year":"2018","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.gene.2025.149966_b0150","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.gene.2025.149966_b0155","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.gene.2025.149966_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gene.2025.149966_b0070","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5129","article-title":"TRIPLE-SWITCH (SWOG\/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924)","volume":"43","author":"Ong","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gene.2025.149966_b0165","unstructured":"FDA approves pembrolizumab for adults and children with TMB-H solid tumors. 2024."},{"key":"10.1016\/j.gene.2025.149966_b0170","unstructured":"FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication. 2024."},{"issue":"12","key":"10.1016\/j.gene.2025.149966_b0175","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.annonc.2024.09.004","article-title":"Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial","volume":"35","author":"van Wilpe","year":"2024","journal-title":"Ann. Oncol."},{"issue":"10295","key":"10.1016\/j.gene.2025.149966_b0180","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.gene.2025.149966_b0185","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.eururo.2024.12.015","article-title":"Final overall survival and molecular data associated with clinical outcomes in patients receiving ipatasertib and abiraterone in the phase 3 IPATential150 trial","volume":"87","author":"de Bono","year":"2025","journal-title":"Eur. Urol."},{"issue":"10276","key":"10.1016\/j.gene.2025.149966_b0190","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.gene.2025.149966_b0195","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.gene.2025.149966_b0210","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.gene.2025.149966_b0215","doi-asserted-by":"crossref","first-page":"290","DOI":"10.5534\/wjmh.230177","article-title":"PARP inhibitors in the treatment of prostate cancer: from scientific rationale to clinical development","volume":"42","author":"Kwon","year":"2024","journal-title":"World J. Mens. Health"},{"issue":"3","key":"10.1016\/j.gene.2025.149966_b0225","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ajur.2022.11.002","article-title":"Cell-free DNA in the management of prostate cancer: current status and future prospective","volume":"10","author":"He","year":"2023","journal-title":"Asian J. Urol."},{"issue":"7035","key":"10.1016\/j.gene.2025.149966_b0230","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.gene.2025.149966_b0235","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1158\/1078-0432.CCR-18-0409","article-title":"A PDX\/organoid biobank of advanced prostate cancers captures genomic and phenotypic heterogeneity for disease modeling and therapeutic screening","volume":"24","author":"Beshiri","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"10459","key":"10.1016\/j.gene.2025.149966_bib352","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.gene.2025.149966_b0240","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3390\/cells8010074","article-title":"Application of prostate cancer models for preclinical study: Advantages and limitations of cell lines, patient-derived xenografts, and three-dimensional culture of patient-derived cells","volume":"8","author":"Namekawa","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.gene.2025.149966_b0245","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1038\/s41467-021-25175-5","article-title":"The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology","volume":"12","author":"Risbridger","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.gene.2025.149966_b0250","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40169-018-0185-6","article-title":"Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs","volume":"7","author":"Maeda","year":"2018","journal-title":"Clin. Transl. Med."},{"issue":"7757","key":"10.1016\/j.gene.2025.149966_b0255","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the cancer cell line encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.gene.2025.149966_b0260","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"7652","key":"10.1016\/j.gene.2025.149966_b0265","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"issue":"10276","key":"10.1016\/j.gene.2025.149966_b0270","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.gene.2025.149966_b0275","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a cancer dependency map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"issue":"6410","key":"10.1016\/j.gene.2025.149966_b0280","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aat5749","article-title":"Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage","volume":"362","author":"Park","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.gene.2025.149966_b0285","doi-asserted-by":"crossref","DOI":"10.4155\/fso.15.72","article-title":"Biomarkers for prostate cancer: present challenges and future opportunities","volume":"2","author":"Sharma","year":"2016","journal-title":"Future Sci. OA"},{"issue":"6","key":"10.1016\/j.gene.2025.149966_b0290","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-17-0853","article-title":"Deep learning-based multi-omics integration robustly predicts survival in liver cancer","volume":"24","author":"Chaudhary","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.gene.2025.149966_b0295","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2017.00084","article-title":"More is better: recent progress in multi-omics data integration methods","volume":"8","author":"Huang","year":"2017","journal-title":"Front. Genet."},{"issue":"2","key":"10.1016\/j.gene.2025.149966_b0300","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cels.2017.08.002","article-title":"Decomposing oncogenic transcriptional signatures to generate maps of divergent cellular states","volume":"5","author":"Kim","year":"2017","journal-title":"Cell Syst."},{"issue":"4","key":"10.1016\/j.gene.2025.149966_b0305","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Cancer Genome Atlas Research","year":"2015","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.gene.2025.149966_b0310","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.cell.2020.09.056","article-title":"Chromatin potential identified by shared single-cell profiling of RNA and chromatin","volume":"183","author":"Ma","year":"2020","journal-title":"Cell"},{"issue":"8067","key":"10.1016\/j.gene.2025.149966_b0315","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41586-025-08866-7","article-title":"Towards conversational diagnostic artificial intelligence","volume":"642","author":"Tu","year":"2025","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.gene.2025.149966_b0320","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"5256","key":"10.1016\/j.gene.2025.149966_b0325","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.gene.2025.149966_b0200","article-title":"LBA6 - Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)","volume":"2025","author":"Tagawa","year":"2025","journal-title":"ESMO"},{"issue":"26","key":"10.1016\/j.gene.2025.149966_b0330","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.gene.2025.149966_b0335","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/ng.3934","article-title":"A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer","volume":"49","author":"Polak","year":"2017","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.gene.2025.149966_b0340","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1158\/1078-0432.CCR-19-2135","article-title":"Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1\/2 mutations","volume":"26","author":"Sztupinszki","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.gene.2025.149966_b0345","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1758834012451205","article-title":"The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies","volume":"4","author":"Hurvitz","year":"2012","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"10","key":"10.1016\/j.gene.2025.149966_b0350","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.23.02112","article-title":"US food and drug administration approval summary: elacestrant for estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer","volume":"42","author":"Shah","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111925007565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111925007565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:22:57Z","timestamp":1768929777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111925007565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":70,"alternative-id":["S0378111925007565"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2025.149966","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating the winding road toward precision prostate cancer care","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2025.149966","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"149966"}}